A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma

Authors
Category Primary study
JournalCancer Research
Year 2014
This article has no abstract
Epistemonikos ID: 08c59f6398a0fc99eadf5a22502bdd6e4630cad8
First added on: Feb 06, 2025